Detalhe da pesquisa
1.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990608
2.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31157964
3.
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Future Oncol
; 17(2): 137-149, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32938232
4.
Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer.
Prostate
; 75(13): 1475-83, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26177841
5.
Carboplatin in Metastatic Castrate Resistant Prostate Cancer: A Retrospective Study of Heavily Pretreated Patients (COMPACT).
Clin Genitourin Cancer
; 22(2): 580-585, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402090
6.
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
J Clin Oncol
; 40(8): 837-846, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928708
7.
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Eur Urol
; 80(3): 275-279, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34030924
8.
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 37(13): 1051-1061, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30817251
9.
A preclinical xenograft model of prostate cancer using human tumors.
Nat Protoc
; 8(5): 836-48, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23558784
10.
A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer.
Biomaterials
; 34(20): 4777-85, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23562048